Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1680
    +0.0024 (+0.20%)
     
  • GBP/USD

    1.2495
    -0.0016 (-0.13%)
     
  • Bitcoin GBP

    51,245.91
    -476.92 (-0.92%)
     
  • CMC Crypto 200

    1,332.70
    -63.83 (-4.57%)
     
  • S&P 500

    5,109.04
    +60.62 (+1.20%)
     
  • DOW

    38,321.24
    +235.44 (+0.62%)
     
  • CRUDE OIL

    83.82
    +0.25 (+0.30%)
     
  • GOLD FUTURES

    2,350.40
    +7.90 (+0.34%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?

In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.